[go: up one dir, main page]

PE20030344A1 - 1-ALQUIL O 1-CICLOALQUIL-TRIAZOLO[4,3-a]QUINAZOLIN-5-ONAS COMO INHIBIDORAS DE FOSFODIESTERASA - Google Patents

1-ALQUIL O 1-CICLOALQUIL-TRIAZOLO[4,3-a]QUINAZOLIN-5-ONAS COMO INHIBIDORAS DE FOSFODIESTERASA

Info

Publication number
PE20030344A1
PE20030344A1 PE2002000722A PE2002000722A PE20030344A1 PE 20030344 A1 PE20030344 A1 PE 20030344A1 PE 2002000722 A PE2002000722 A PE 2002000722A PE 2002000722 A PE2002000722 A PE 2002000722A PE 20030344 A1 PE20030344 A1 PE 20030344A1
Authority
PE
Peru
Prior art keywords
alkyl
quinazolin
triazolo
cycloalkyl
onas
Prior art date
Application number
PE2002000722A
Other languages
English (en)
Inventor
Bernard Gaudilliere
Remi Lavalette
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20030344A1 publication Critical patent/PE20030344A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DE 1-ALQUIL O 1-CICLOALQUIL-TRIAZOLO[4,3-a]QUINAZOLIN-5-ONAS DE FORMULA I DONDE R1 ES OH, HALO, NITRO, MERCAPTO, CIANO, CARBOXILO, ALQUILO, ALCOXI, NR4R5 DONDE R4 Y R5 SON H, ALQUILO, ENTRE OTROS; R2 ES ALQUILO INFERIOR CON OR9, SR9; -X2-CICLOALQUILO CON OR9, SR9, NR9R10 CON ALQUILO C1-C4 LINEAL O RAMIFICADO DONDE R9 Y R10 SON H, ALQUILO Y X2 UN ENLACE ALQUILENO C1-C4; R3 ES -(CH2)n-Ar(Y1)(Y2)(Y3) DONDE n ES 1-4, Ar ES UN ANILLO AROMATICO DE 5-6 ATOMOS CON 0-3 HETEROATOMOS; Y1, Y2, Y3 SON H, OH, MERCAPTO, NITRO, HALOGENO, ALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 4-BENCIL-1-CICLOPENTIL-7-(CICLOPENTILFORMAMIDO)-4H-[1,2,4]TRIAZOLO[4,3-a]QUINAZOLIN-5-ONA, 7-ACETAMIDO-4-BENCIL-1-CICLOPENTIL-4H-[1,2,4]TRIAZOLO[4,3-a]QUINAZOLIN-5-ONA, 4-BENCIL-7-(CICLOPENTILFORMAMIDO)-1-METIL-4H-[1,2,4]TRIAZOLO[4,3-a]QUINAZOLIN-5-ONA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION Y COMPUESTOS INTERMEDIOS. LOS COMPUESTOS MENCIONADOS SON INHIBIDORES DE LA FOSFODIESTERASA PDE4 UTIL PARA EL TRATAMIENTO DE CANCER, ARTRITIS, EPOC
PE2002000722A 2001-08-13 2002-08-09 1-ALQUIL O 1-CICLOALQUIL-TRIAZOLO[4,3-a]QUINAZOLIN-5-ONAS COMO INHIBIDORAS DE FOSFODIESTERASA PE20030344A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01402166A EP1285922A1 (en) 2001-08-13 2001-08-13 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
PE20030344A1 true PE20030344A1 (es) 2003-04-10

Family

ID=8182851

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000722A PE20030344A1 (es) 2001-08-13 2002-08-09 1-ALQUIL O 1-CICLOALQUIL-TRIAZOLO[4,3-a]QUINAZOLIN-5-ONAS COMO INHIBIDORAS DE FOSFODIESTERASA

Country Status (12)

Country Link
US (1) US6747035B2 (es)
EP (2) EP1285922A1 (es)
JP (1) JP2005502662A (es)
AR (1) AR036258A1 (es)
BR (1) BR0211863A (es)
CA (1) CA2453647A1 (es)
DO (1) DOP2002000447A (es)
HN (1) HN2002000208A (es)
PA (1) PA8552501A1 (es)
PE (1) PE20030344A1 (es)
SV (1) SV2003001173A (es)
WO (1) WO2003016314A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050122220A (ko) 2003-03-25 2005-12-28 다케다 샌디에고, 인코포레이티드 디펩티딜 펩티다제 억제제
BRPI0413452A (pt) 2003-08-13 2006-10-17 Takeda Pharmaceutical composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
CN102079743B (zh) 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
WO2006068978A2 (en) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
GEP20135838B (en) 2005-09-14 2013-06-10 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors usage at diabetes treatment
CA2622642C (en) 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US8324383B2 (en) * 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
KR102062824B1 (ko) * 2006-09-13 2020-01-07 다케다 야쿠힌 고교 가부시키가이샤 2-［6-(3-아미노-피페리딘-1-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2ｈ-피리미딘-1-일메틸］-4-플루오로-벤조니트릴의 용도
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) * 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US20100144140A1 (en) * 2008-12-10 2010-06-10 Novellus Systems, Inc. Methods for depositing tungsten films having low resistivity for gapfill applications
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
MA38333A1 (fr) 2013-02-19 2017-02-28 Pfizer Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
SG11201700243YA (en) 2014-08-06 2017-02-27 Pfizer Imidazopyridazine compounds
DK3310784T3 (da) * 2015-06-17 2020-11-09 Pfizer Tricykliske forbindelser og deres anvendelse som phosphodiesterasehæmmere
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
EP3883636A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD158549A1 (de) * 1981-05-13 1983-01-19 Karl Kottke Verfahren zur herstellung von 1,4,7,9-verschieden substituierten 4,5-dihydro-s-triazolo(4,3-a)chinazolin-5-onen
IL66835A (en) * 1981-09-24 1988-05-31 Roussel Uclaf 1,4-disubstituted(1,2,4)triazolo(4,3-alpha)quinazolin-5(4h)-one derivatives and their salts,their preparation and pharmaceutical compositions containing them
US6492364B1 (en) * 1998-12-04 2002-12-10 Toray Industries, Inc. Triazolo and derivatives as chemokine inhibitors
FR2792938B1 (fr) * 1999-04-28 2001-07-06 Warner Lambert Co NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV

Also Published As

Publication number Publication date
AR036258A1 (es) 2004-08-25
BR0211863A (pt) 2004-09-21
CA2453647A1 (en) 2003-02-27
PA8552501A1 (es) 2003-06-30
US20030069260A1 (en) 2003-04-10
EP1285922A1 (en) 2003-02-26
SV2003001173A (es) 2003-04-03
HN2002000208A (es) 2003-02-27
EP1419159A1 (en) 2004-05-19
DOP2002000447A (es) 2003-02-15
JP2005502662A (ja) 2005-01-27
WO2003016314A1 (en) 2003-02-27
US6747035B2 (en) 2004-06-08

Similar Documents

Publication Publication Date Title
PE20030344A1 (es) 1-ALQUIL O 1-CICLOALQUIL-TRIAZOLO[4,3-a]QUINAZOLIN-5-ONAS COMO INHIBIDORAS DE FOSFODIESTERASA
MXPA04003886A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.
ATE365740T1 (de) Substituierte pyrazolopyrimidine
DE60112974D1 (en) Carbolinderivate
PL369530A1 (en) Chemical compounds
FR17C0003I2 (fr) Steroides comme agonistes de fxr
DK0640592T3 (da) N-acylerede tricycliske azaheteroringe anvendelige som vasopressin-antagonister
UY27079A1 (es) Procedimiento para la preparación de un anticolinérgico
GT200000069A (es) Derivados heterociclicos utiles como agentes anticancerosos.
AR072756A2 (es) Intermediarios para la preparacion; derivados de triazolo[4,5-d]pirimidina, utiles como antitromboticos
BR0211805A (pt) Herbicidas
PE20011066A1 (es) PIRIDO [2,3-d] PIRIMIDIN-2,7-DIAMINAS INHIBIDORES DE CINASAS
AP2001002205A0 (en) Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase.
DE60216233D1 (en) Carbolinderivate
GB0127903D0 (en) Improvements relating to organic compounds
ES2192768T3 (es) Procedimiento de produccion de hidrocarburos halogenados.
AR033753A1 (es) Derivados de imidazo[1,5-a]pirimido[5,4-d]benzazepina
EA200300593A1 (ru) Соединения пиперазинилпиразинов в качестве агонистов или антагонистов серотонин 5-ht2 рецептора
AR061492A2 (es) Procedimiento para la preparacion de compuestos intermediarios para la preparacion de 5-amino-1-aril-3-ciano pirazoles
MXPA02012659A (es) Derivados de pirazindiona condensados.
PE20030664A1 (es) DERIVADOS DE TRIAZOLO [4,3-a]PIRIDO[2,3-d]PIRIMIDIN-5-ONA, COMPOSICIONES QUE LOS CONTIENEN, METODO DE PREPARACION Y USO
PT1028950E (pt) Quinazolina-2,4-dionas 7-substituidas uteis como agentes antibacterianos
PA8441401A1 (es) Procedimiento para piridinas sustituidas
MXPA02012472A (es) Compuestos quimicos.
PA8519801A1 (es) Nuevo procedimiento para la preparacion de pirazolopirimidinonas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal